# Impact of Switching to Continuous Release Dopamine Agonists

> **NCT00465452** · PHASE3 · COMPLETED · sponsor: **University of Toledo** · enrollment: 11 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Continuous Release Dopamine Agonists

## Key facts

- **NCT ID:** NCT00465452
- **Lead sponsor:** University of Toledo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-03
- **Final completion:** 2011-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00465452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00465452, "Impact of Switching to Continuous Release Dopamine Agonists". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00465452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*